AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

PRESCIENT THERAPEUTICS LTD

0.058

-0.002-3.33%

Volume:766.56K

Turnover:45.28K

Market Cap:60.99M

PE:-5.88

High:0.065

Open:0.065

Low:0.057

Close:0.060

52wk High:0.125

52wk Low:0.038

Shares:1.05B

Float Shares:863.70M

Volume Ratio:0.62

T/O Rate:0.09%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.010

EPS(LYR):-0.009

ROE:-54.33%

ROA:-31.75%

PB:3.59

PE(LYR):-6.38

Loading ...

Overview Company News Filings

Prescient Therapeutics Secures European Authorization to Start Clinical Trial in Italy; Shares Hit Two-Year High

MT Newswires Live

BRIEF-Prescient Therapeutics Secures EU Authorisation To Commence PTX-100 Clinical Trial

BUZZ-Australia's Prescient Therapeutics hits two-year high on EU nod for cancer therapy

Prescient Therapeutics - Secures EU Authorisation to Commence Ptx-100 Clinical Trial

THOMSON REUTERS

BUZZ-Australia's Prescient Therapeutics soars on EU orphan drug tag for cancer therapy

BRIEF-Prescient Therapeutics Secures EU Orphan Drug Designation For PTX-100

Prescient Therapeutics Ltd-Ptx Secures EU Orphan Drug Designation for Ptx-100 in Ctcl

THOMSON REUTERS

BRIEF-Prescient Therapeutics Seeks Trading Halt

Prescient Therapeutics - Raises a$6.8 Mln in Share Purchase Plan

THOMSON REUTERS

Prescient Therapeutics Ltd-Prescient Announces Results of Spp & Launches Placement

THOMSON REUTERS

Prescient Therapeutics - Enters Trading Halt for Follow-on Placement at a$0.04 per Share

THOMSON REUTERS

Prescient Therapeutics Completes Initiation Visit at US Site

MT Newswires Live

Notification of cessation of securities - PTX-PTX.AX

Notification of cessation of securities - PTX-PTX.AX

Prescient Share Purchase Plan Investor Presentation-PTX.AX

ASX ALERT-Prescient Therapeutics Opens Share Purchase Plan-PTX.AX

BRIEF-Prescient Therapeutics To Raise A$7 Million

Proposed issue of securities - PTX-PTX.AX

ASX ALERT-Prescient Therapeutics Launches Share Purchase Plan for $7m-PTX.AX

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PTX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PTX.AU\",,,,,undefined,":{"symbol":"PTX.AU","market":"AU","secType":"STK","nameCN":"PRESCIENT THERAPEUTICS LTD","latestPrice":0.058,"timestamp":1773724320000,"preClose":0.06,"halted":0,"volume":766555,"delay":0,"changeRate":-0.03333333333333325,"nameEN":"PRESCIENT THERAPEUTICS LTD","floatShares":863697911,"shares":1051514543,"eps":-0.00987,"marketStatus":"Not Yet Opened","change":-0.002,"latestTime":"03-17 16:12:00 AEDT","open":0.065,"high":0.065,"low":0.057,"amount":45278,"amplitude":0.133333,"askPrice":0.06,"askSize":274791,"bidPrice":0.057,"bidSize":6000,"shortable":3,"etf":0,"ttmEps":-0.00987,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1773788400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.06,"openAndCloseTimeList":[[1773702000000,1773723600000]],"volumeRatio":0.621444,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"PTX.AU","preClose":0.06,"auctionPrice":0.058,"auctionVolume":82850,"auction":3,"marketStatus":"盘后竞价","timestamp":1773724192207}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PTX.AU\",,,,,undefined,":{"symbol":"PTX.AU","floatShares":863697911,"roa":"-31.75%","roe":"-54.33%","lyrEps":-0.009092,"volumeRatio":0.621444,"shares":1051514543,"dividePrice":0,"high":0.065,"amplitude":0.133333,"preClose":0.06,"low":0.057,"week52Low":0.038,"pbRate":"3.59","psRate":"14.30","week52High":0.125,"institutionHeld":0,"latestPrice":0.058,"committee":-0.957264,"eps":-0.00987,"divideRate":0,"volume":766555,"delay":0,"ttmEps":-0.00987,"open":0.065,"prevYearClose":0.084,"prevWeekClose":0.058,"prevMonthClose":0.068,"prevQuarterClose":0.084,"fiveDayClose":0.059,"twentyDayClose":0.062,"sixtyDayClose":0.1,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTX.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2591691830","title":"Prescient Therapeutics Secures European Authorization to Start Clinical Trial in Italy; Shares Hit Two-Year High","url":"https://stock-news.laohu8.com/highlight/detail?id=2591691830","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591691830?lang=en_us&edition=fundamental","pubTime":"2025-12-15 11:06","pubTimestamp":1765767988,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics (ASX:PTX) secured authorization from the European Clinical Trials Information System to begin its clinical trial for cancer drug candidate PTX-100 in patients with relapsed/refr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK4139","BK4007","BK4539","BK7067","PTX.AU","LENZ"],"gpt_icon":0},{"id":"2591869306","title":"BRIEF-Prescient Therapeutics Secures EU Authorisation To Commence PTX-100 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591869306","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591869306?lang=en_us&edition=fundamental","pubTime":"2025-12-15 09:24","pubTimestamp":1765761878,"startTime":"0","endTime":"0","summary":"BRIEF-Prescient Therapeutics Secures EU Authorisation To Commence PTX-100 Clinical TrialDec 15 (Reuters) - Prescient Therapeutics Ltd PTX.AX:SECURES EU AUTHORISATION TO COMMENCE PTX-100 CLINICAL TRIALFurther company coverage: PTX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XJ00D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTX.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2591698706","title":"BUZZ-Australia's Prescient Therapeutics hits two-year high on EU nod for cancer therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2591698706","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591698706?lang=en_us&edition=fundamental","pubTime":"2025-12-15 08:56","pubTimestamp":1765760176,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Prescient Therapeutics hits two-year high on EU nod for cancer therapy** Shares of Australia's Prescient Therapeutics PTX.AX rise as much as 11.2% to A$0.099, their highest since earl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL6N3XL01Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","PTX.AU","BK7508"],"gpt_icon":0},{"id":"2591662031","title":"Prescient Therapeutics - Secures EU Authorisation to Commence Ptx-100 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591662031","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591662031?lang=en_us&edition=fundamental","pubTime":"2025-12-15 06:11","pubTimestamp":1765750266,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251214:nFWN3XJ00D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","PTX.AU"],"gpt_icon":0},{"id":"2584960552","title":"BUZZ-Australia's Prescient Therapeutics soars on EU orphan drug tag for cancer therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2584960552","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584960552?lang=en_us&edition=fundamental","pubTime":"2025-11-19 08:41","pubTimestamp":1763512912,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Prescient Therapeutics soars on EU orphan drug tag for cancer therapy** Shares of Prescient Therapeutics PTX.AX rise as much as 29.2% to A$0.062, their highest level since December 23, 2024** Clinical-stage oncology company heading for best day since December 2024, if gains hold** Co says European Medicines Agency grants orphan drug designation to PTX-100 for treating cutaneous T-cell lymphoma** About 4.4 million shares change hand, 3.9x 30-day average** Stock up 10% this year, including the day's move  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nL6N3WV00V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","PTX.AU","BK7508"],"gpt_icon":0},{"id":"2584969925","title":"BRIEF-Prescient Therapeutics Secures EU Orphan Drug Designation For PTX-100","url":"https://stock-news.laohu8.com/highlight/detail?id=2584969925","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584969925?lang=en_us&edition=fundamental","pubTime":"2025-11-19 06:04","pubTimestamp":1763503448,"startTime":"0","endTime":"0","summary":"BRIEF-Prescient Therapeutics Secures EU Orphan Drug Designation For PTX-100Nov 19 (Reuters) - Prescient Therapeutics Ltd PTX.AX:PTX SECURES EU ORPHAN DRUG DESIGNATION FOR PTX-100 IN CTCLFurther company coverage: PTX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nTUE6THPBP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","PTX.AU","BK7508"],"gpt_icon":0},{"id":"2584296999","title":"Prescient Therapeutics Ltd-Ptx Secures EU Orphan Drug Designation for Ptx-100 in Ctcl","url":"https://stock-news.laohu8.com/highlight/detail?id=2584296999","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584296999?lang=en_us&edition=fundamental","pubTime":"2025-11-19 06:02","pubTimestamp":1763503360,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nTUE6THPBP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","PTX.AU","BK7067"],"gpt_icon":0},{"id":"2555070040","title":"BRIEF-Prescient Therapeutics Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2555070040","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555070040?lang=en_us&edition=fundamental","pubTime":"2025-07-29 09:06","pubTimestamp":1753751188,"startTime":"0","endTime":"0","summary":"BRIEF-Prescient Therapeutics Seeks Trading Halt July 29 (Reuters) - Prescient Therapeutics Ltd PTX.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON  CAPITAL RAISEFurther company coverage: PTX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nFWN3TP26D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","PTX.AU"],"gpt_icon":0},{"id":"2555776702","title":"Prescient Therapeutics - Raises a$6.8 Mln in Share Purchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2555776702","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555776702?lang=en_us&edition=fundamental","pubTime":"2025-07-29 07:54","pubTimestamp":1753746895,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nTUE98CYQL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTX.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2555702775","title":"Prescient Therapeutics Ltd-Prescient Announces Results of Spp & Launches Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2555702775","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555702775?lang=en_us&edition=fundamental","pubTime":"2025-07-29 07:54","pubTimestamp":1753746895,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nTUE98CYQL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PTX.AU","BK7508"],"gpt_icon":0},{"id":"2555027727","title":"Prescient Therapeutics - Enters Trading Halt for Follow-on Placement at a$0.04 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2555027727","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555027727?lang=en_us&edition=fundamental","pubTime":"2025-07-29 07:54","pubTimestamp":1753746895,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nTUE98CYQL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PTX.AU","BK7508"],"gpt_icon":0},{"id":"2551152621","title":"Prescient Therapeutics Completes Initiation Visit at US Site","url":"https://stock-news.laohu8.com/highlight/detail?id=2551152621","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551152621?lang=en_us&edition=fundamental","pubTime":"2025-07-16 09:48","pubTimestamp":1752630522,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics  has completed a site initiation visit at the VCU Massey Comprehensive Cancer Center in Virginia for its ongoing Phase 2a clinical trial of drug candidate PTX-100 in patients with relapsed or refractory cutaneous T-cell lymphoma, according to a Wednesday filing with the Australian bourse.Additional US sites are expected to be initiated in the coming weeks, the filing said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","PTX.AU","BK7067","BK4007","BK7508","LENZ","BK4139"],"gpt_icon":0},{"id":"2551730719","title":"Notification of cessation of securities - PTX-PTX.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2551730719","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551730719?lang=en_us&edition=fundamental","pubTime":"2025-07-14 11:33","pubTimestamp":1752464008,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250714:nASXbq8yj3","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nASX7PBwf6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","PTX.AU","BK7508"],"gpt_icon":0},{"id":"2549598318","title":"Notification of cessation of securities - PTX-PTX.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2549598318","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549598318?lang=en_us&edition=fundamental","pubTime":"2025-07-08 10:00","pubTimestamp":1751940011,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250708:nASX9MkVPl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nASXy356Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","PTX.AU"],"gpt_icon":0},{"id":"2548333302","title":"Prescient Share Purchase Plan Investor Presentation-PTX.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548333302","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548333302?lang=en_us&edition=fundamental","pubTime":"2025-07-04 07:19","pubTimestamp":1751584763,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250703:nASX9JZ7D5","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nASX262Mb0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","PTX.AU","BK7067"],"gpt_icon":0},{"id":"2548354836","title":"ASX ALERT-Prescient Therapeutics Opens Share Purchase Plan-PTX.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548354836","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548354836?lang=en_us&edition=fundamental","pubTime":"2025-07-02 07:21","pubTimestamp":1751412096,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250701:nASX1jyFRD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nASX8bWFR4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","PTX.AU"],"gpt_icon":0},{"id":"2548046430","title":"BRIEF-Prescient Therapeutics To Raise A$7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2548046430","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548046430?lang=en_us&edition=fundamental","pubTime":"2025-07-01 07:26","pubTimestamp":1751325987,"startTime":"0","endTime":"0","summary":"BRIEF-Prescient Therapeutics To Raise A$7 MillionJuly 1 (Reuters) - Prescient Therapeutics Ltd PTX.AX:TO RAISE A$7 MILLION VIA A SHARE PURCHASE PLAN AT A$0.040 PER SHAREFurther company coverage: PTX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nFWN3SX14X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","PTX.AU","BK7067"],"gpt_icon":0},{"id":"2548462260","title":"Proposed issue of securities - PTX-PTX.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548462260","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548462260?lang=en_us&edition=fundamental","pubTime":"2025-07-01 07:10","pubTimestamp":1751325044,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nASX287WSg","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nASX708S3T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","PTX.AU"],"gpt_icon":0},{"id":"2548046240","title":"ASX ALERT-Prescient Therapeutics Launches Share Purchase Plan for $7m-PTX.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548046240","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548046240?lang=en_us&edition=fundamental","pubTime":"2025-07-01 07:10","pubTimestamp":1751325026,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nASX8yFZV9","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nASX8p6bzP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","PTX.AU","BK7508"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}]}}